Rasmus Borgquist, Maiwand Farouq, Hanna Markstad, Johan Brandt, David Mörtsell, Steen Jensen, Uzma Chaudhry, Lingwei Wang
{"title":"Diagnosis and treatment of the rare procedural complication of malpositioned pacing leads in the left heart: a single center experience.","authors":"Rasmus Borgquist, Maiwand Farouq, Hanna Markstad, Johan Brandt, David Mörtsell, Steen Jensen, Uzma Chaudhry, Lingwei Wang","doi":"10.1080/14017431.2022.2099013","DOIUrl":"https://doi.org/10.1080/14017431.2022.2099013","url":null,"abstract":"<p><p><i>Objectives</i>. This study assessed the management approach and outcome of the pacemaker or implantable cardioverter-defibrillator (ICD) leads malpositioned in the left heart. Malpositioned leads (MPLs) may have deleterious consequences, and appropriate management remains uncertain. <i>Methods</i>. The study population included all patients referred to a single institution for MPL in the left side of the heart after pacemaker or ICD implantation during the period from 2015 to 2021. The approach and outcome of lead management were retrospectively assessed. <i>Results</i>. During the study period, 6887 patients underwent device implantation. MPL was diagnosed in five patients (0.07%). In four cases, the pacing lead was placed in a coronary sinus (CS) branch, while the pacing lead was inside the left ventricle (LV) in one case. Symptoms suggestive of lead malposition were reported by 2 patients (40%). One of the patients presented with recurrent TIAs. Another presented with inappropriate ICD shocks. In one asymptomatic case, an ICD lead changed position from the right ventricle to the CS, suggesting idiopathic lead migration. In 4/5 patients, the leads were removed or repositioned by percutaneous approach, with no major periprocedural complications. <i>Conclusions</i>. In this series of MPL in the left heart, two patients presented with thromboembolic events or inappropriate ICD shocks. These serious complications highlight the critical need for early correct diagnosis and proper management of MPL.</p>","PeriodicalId":137876,"journal":{"name":"Scandinavian cardiovascular journal : SCJ","volume":" ","pages":"302-309"},"PeriodicalIF":2.2,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40635502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Charlotta Lans, Åsa Cider, Eva Nylander, Lars Brudin
{"title":"The relationship between six-minute walked distance and health-related quality of life in patients with chronic heart failure.","authors":"Charlotta Lans, Åsa Cider, Eva Nylander, Lars Brudin","doi":"10.1080/14017431.2022.2107234","DOIUrl":"https://doi.org/10.1080/14017431.2022.2107234","url":null,"abstract":"<p><p><i>Objectives</i>. To assess the relationship between the six-minute walk test (6MWT) and health-related quality of life (HRQL) in patients with chronic heart failure. <i>Methods</i>. Forty-six patients (37 men and 9 women) with chronic heart failure, mean age 68 (SD 9), NYHA II-III and EF 29 (9) % were included. They performed 6MWT and assessed HRQL using two tools, a Swedish version of the 36-item Short Form (SF-36) and the Minnesota Living with Heart Failure Questionnaire (MLHFQ). This was performed repeatedly during a study period of one year. <i>Results</i>. Patients with a walking distance lower than median experienced a lower HRQL than the higher performing half of the cohort, in four dimensions of the SF-36 and the summary of physical and mental components, but not in the dimensions of MLHFQ. <i>Conclusion</i>. Patients with heart failure with a short walking distance assessed their quality of life as inferior in half of the dimensions in the SF-36 but not in the dimensions measured with the MLHFQ. Thus, different aspects of the symptomatology are uncovered using the 6MWT and the different HRQL tools.</p>","PeriodicalId":137876,"journal":{"name":"Scandinavian cardiovascular journal : SCJ","volume":" ","pages":"310-315"},"PeriodicalIF":2.2,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40671826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L Gronningsaeter, H Skulstad, A Quattrone, E Langesaeter, M E Estensen
{"title":"Reduced left ventricular function and sustained hypertension in women seven years after severe preeclampsia.","authors":"L Gronningsaeter, H Skulstad, A Quattrone, E Langesaeter, M E Estensen","doi":"10.1080/14017431.2022.2099012","DOIUrl":"https://doi.org/10.1080/14017431.2022.2099012","url":null,"abstract":"<p><p><i>Objective</i>. To study left ventricular (LV) function and blood pressure (BP) at a long-term follow-up in women after severe pre-eclampsia. <i>Design</i>. In this single-centre, cross-sectional study, 96 patients were eligible for inclusion. LV function was examined by transthoracic echocardiography including tissue Doppler echocardiography and speckle tracking. BP was measured at rest using repeated non-invasive techniques. <i>Results</i>. We compared 36 patients with early-onset and 33 patients with late-onset pre-eclampsia with 28 healthy controls. Mean age (40 ± 3 years) and median time since delivery (7 ± 2 years) were similar across the study groups. The patients had 18% higher systolic BP (139 ± 15 mmHg) and 24% higher diastolic BP (87 ± 19 mmHg) than controls (<i>p</i> < .01). Hypertension was present in 23 patients (33%), where the estimated LV mass was 16% higher (<i>p</i> = .05) than in controls. The LV ejection fraction was 19% lower in the early-onset group (51 ± 4%; <i>p</i> = .01) and 14% lower in the late-onset group (54 ± 6; <i>p</i> = .04) compared with controls. LV global longitudinal strain was 18% lower in the patient group (-17.7 ± 2.1%) compared with controls (<i>p</i> = .01). Indicative of a more restrictive filling pattern, the diastolic indices showed a lower e' mean (<i>p</i> < .01) and subsequently higher E/e' ratio (<i>p</i> < .01). There were no significant differences in BP, systolic or diastolic function indices between the patient groups. <i>Conclusion</i>. We found sustained hypertension, higher LV mass and reduced LV systolic and diastolic function 7 y after severe pre-eclampsia. Our findings emphasize the importance of early risk stratification and clinical counselling, and follow-up for such cases.</p>","PeriodicalId":137876,"journal":{"name":"Scandinavian cardiovascular journal : SCJ","volume":" ","pages":"292-301"},"PeriodicalIF":2.2,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40616472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jan Gröschel, Clemens Ammann, Leonora Zange, Darian Viezzer, Christoph Forman, Michaela Schmidt, Edyta Blaszczyk, Jeanette Schulz-Menger
{"title":"Fast acquisition of left and right ventricular function parameters applying cardiovascular magnetic resonance in clinical routine - validation of a 2-shot compressed sensing cine sequence.","authors":"Jan Gröschel, Clemens Ammann, Leonora Zange, Darian Viezzer, Christoph Forman, Michaela Schmidt, Edyta Blaszczyk, Jeanette Schulz-Menger","doi":"10.1080/14017431.2022.2099010","DOIUrl":"https://doi.org/10.1080/14017431.2022.2099010","url":null,"abstract":"<p><p><i>Objectives.</i> To evaluate if cine sequences accelerated by compressed sensing (CS) are feasible in clinical routine and yield equivalent cardiac morphology in less time. <i>Design.</i> We evaluated 155 consecutive patients with various cardiac diseases scanned during our clinical routine. LV and RV short axis (SAX) cine images were acquired by conventional and prototype 2-shot CS sequences on a 1.5 T CMR. The 2-shot prototype captures the entire heart over a period of 3 beats making the acquisition potentially even faster. Both scans were performed with identical slice parameters and positions. We compared LV and RV morphology with Bland-Altmann plots and weighted the results in relation to pre-defined tolerance intervals. Subjective and objective image quality was evaluated using a 4-point score and adapted standardized criteria. Scan times were evaluated for each sequence. <i>Results.</i> In total, no acquisitions were lost due to non-diagnostic image quality in the subjective image score. Objective image quality analysis showed no statistically significant differences. The scan time of the CS cines was significantly shorter (<i>p</i> < .001) with mean scan times of 178 ± 36 s compared to 313 ± 65 s for the conventional cine. All cardiac function parameters showed excellent correlation (<i>r</i> 0.978-0.996). Both sequences were considered equivalent for the assessment of LV and RV morphology. <i>Conclusions.</i> The 2-shot CS SAX cines can be used in clinical routine to acquire cardiac morphology in less time compared to the conventional method, with no total loss of acquisitions due to nondiagnostic quality.</p><p><strong>Trial registration: </strong>ISRCTN12344380. Registered 20 November 2020, retrospectively registered.</p>","PeriodicalId":137876,"journal":{"name":"Scandinavian cardiovascular journal : SCJ","volume":" ","pages":"266-275"},"PeriodicalIF":2.2,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40506686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Expanding the evidence base of new cardiovascular treatments by systematic registry-based evaluation of their implementation in clinical practice.","authors":"Björn Redfors, Elmir Omerovic","doi":"10.1080/14017431.2022.2100474","DOIUrl":"https://doi.org/10.1080/14017431.2022.2100474","url":null,"abstract":"Health care resources are limited. It is therefore important to distinguish cost-effective and life-saving new treatments from costly but ineffective treatments, or costly treatments that are no more effective than less expensive alternatives. Unfortunately, few new treatments are systematically evaluated after they are implemented in clinical practice. We advocate for systematic large-scale evaluation of the efficacy and safety of new treatments when they are introduced in clinical practice; by pragmatic, cluster-randomized implementation strategies followed up through health care registries. Randomized controlled trials (RCTs) represent robust and important tools for assuring that a new treatment is efficacious and safe prior to its implementation in clinical care, but even well-conducted RCTs rarely fully establish the efficacy and safety of treatment across different subsets of patients [1]. Furthermore, the RCTs that form the evidence base for the implementation of new treatments are often funded and conducted by profit-seeking organizations, a fact that arguably further justifies the continued evaluation of the performance of these treatments. Despite persisting uncertainties in their efficacy and safety at the time of their implementation in clinical practice, few treatments are systematically evaluated after their implementation [2]. Several treatments that were found to be inefficacious compared to less expensive alternatives many years after they were implemented could have been identified as ineffective earlier if they had been systematically evaluated when they were implemented [3]. Once a new treatment has been shown to be efficacious and safe in a traditional RCT, healthcare registries can be used as data capture systems to allow inexpensive further evaluation of the efficacy and safety of new treatments if the implementation of the treatment is done systematically using a cluster-randomized approach [4]. Cluster randomized designs represent flexible means of systematically implementing new treatments, by randomizing individual hospitals or health care regions (clusters of patients) to different treatments (parallel group design) or to the order in which they implement a new treatment (stepped wedge design) [5]. To reliably evaluate the implementation of a new treatment in a health care registry, the registry must be of sufficient detail and quality to allow for identification of the desired study population and reliable endpoint ascertainment. Some contemporary health care registries, such as the nationwide Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART), fulfill these criteria [4]. By systematically introducing new treatments using a cluster randomized approach and following up outcomes in already existing health registries, data can be acquired for a substantial number of patients at minimal cost. Clusterrandomized implementation ","PeriodicalId":137876,"journal":{"name":"Scandinavian cardiovascular journal : SCJ","volume":" ","pages":"264-265"},"PeriodicalIF":2.2,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40529886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Giulia Ferrannini, Mariam Almosawi, Kåre Buhlin, Ulf De Faire, Barbro Kjellström, Björn Klinge, Åke Nygren, Per Näsman, Elisabet Svenungsson, Lars Rydén, Anna Norhammar
{"title":"Long-term prognosis after a first myocardial infarction: eight years follow up of the case-control study PAROKRANK.","authors":"Giulia Ferrannini, Mariam Almosawi, Kåre Buhlin, Ulf De Faire, Barbro Kjellström, Björn Klinge, Åke Nygren, Per Näsman, Elisabet Svenungsson, Lars Rydén, Anna Norhammar","doi":"10.1080/14017431.2022.2112072","DOIUrl":"https://doi.org/10.1080/14017431.2022.2112072","url":null,"abstract":"<p><p><i>Objective.</i> To explore long-term cardiovascular outcomes and mortality in patients after a first myocardial infarction (MI) compared with matched controls in a contemporary setting. <i>Methods</i>. During 2010-2014 the Swedish study PAROKRANK recruited 805 patients <75 years with a first MI and 805 age-, gender-, and area-matched controls. All study participants were followed until 31 December 2018, through linkage with the National Patient Registry and the Cause of Death Registry. The primary endpoint was the first of a composite of all-cause death, non-fatal MI, non-fatal stroke, and heart failure hospitalization. Event rates in cases and controls were calculated using a Cox regression model, subsequently adjusted for baseline smoking, education level, and marital status. Kaplan-Meier curves were computed and compared by log-rank test. <i>Results</i>. A total of 804 patients and 800 controls (mean age 62 years; women 19%) were followed for a mean of 6.2 (0.2-8.5) years. The total number of primary events was 211. Patients had a higher event rate than controls (log-rank test <i>p</i> < .0001). Adjusted hazard ratio (HR) for the primary outcome was 2.04 (95% CI 1.52-2.73). Mortality did not differ between patients (<i>n</i> = 38; 4.7%) and controls (<i>n</i> = 35; 4.4%). A total of 82.5% patients and 91.3% controls were event-free during the follow up. <i>Conclusions</i>. In this long-term follow up of a contemporary, case-control study, the risk for cardiovascular events was higher in patients with a previous first MI compared with their matched controls, while mortality did not differ. The access to high quality of care and cardiac rehabilitation might partly explain the low rates of adverse outcomes.</p>","PeriodicalId":137876,"journal":{"name":"Scandinavian cardiovascular journal : SCJ","volume":" ","pages":"337-342"},"PeriodicalIF":2.2,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40419858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The impact of chronic kidney disease severity on clinical outcomes after current generation drug-eluting stent implantation for left main distal bifurcation lesions: the Milan and New-Tokyo registry.","authors":"Yusuke Watanabe, Satoru Mitomo, Toru Naganuma, Kensuke Takagi, Hiroyoshi Kawamoto, Satoshi Matsuoka, Alaide Chieffo, Matteo Montorfano, Sunao Nakamura, Antonio Colombo","doi":"10.1080/14017431.2022.2084561","DOIUrl":"https://doi.org/10.1080/14017431.2022.2084561","url":null,"abstract":"<p><p><i>Objectives</i>. The impact of chronic kidney disease (CKD) on clinical outcomes after percutaneous coronary intervention (PCI) for unprotected left main distal bifurcation lesions (ULMD) is not fully understood in current generation drug eluting stent (cDES) era. We assessed clinical outcomes after PCI using cDES for ULMD according to CKD severity based on estimated glomerular filtration rate (eGFR). <i>Design</i>. We identified 720 consecutive patients who underwent PCI using cDES for ULMD at three high volume centers between January 2005 and December 2015. We divided those patients to the following five groups according to eGFR. Each group was defined as follows: no CKD (60 mL/min/1.73 m<sup>2</sup> ≤ eGFR), mild CKD (45 ≤ eGFR < 60 mL/min/1.73 m<sup>2</sup>), moderate CKD (30 ≤ eGFR < 45 mL/min/1.73 m<sup>2</sup>), severe CKD (15 ≤ eGFR < 30 mL/min/1.73 m<sup>2</sup>) and hemodialysis (HD). The primary endpoint was target lesion failure (TLF) at 3 years. TLF was defined as a composite of cardiac death, target lesion revascularization (TLR) and myocardial infarction (MI). <i>Results</i>. TLF occurred more frequently in severe CKD and HD group compared with other three groups. <i>Conclusions</i>. The patients who have severe CKD or are on HD, were extremely associated with worse clinical outcomes after PCI for ULMD even with cDES.</p>","PeriodicalId":137876,"journal":{"name":"Scandinavian cardiovascular journal : SCJ","volume":" ","pages":"236-242"},"PeriodicalIF":2.2,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40479629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Peter Bo Poulsen, Ulla Hemmingsen, Tine Anette Melgaard, Heidi Buch Elleby, Dorte Wedell-Wedellsborg, Lars Dybro, Ida Marie Lund, Ulrik Dixen, Lars Frost
{"title":"Feasibility of screening for atrial fibrillation in a domiciliary setting: opportunistic one-time screening at preventive home visits in municipalities.","authors":"Peter Bo Poulsen, Ulla Hemmingsen, Tine Anette Melgaard, Heidi Buch Elleby, Dorte Wedell-Wedellsborg, Lars Dybro, Ida Marie Lund, Ulrik Dixen, Lars Frost","doi":"10.1080/14017431.2022.2095016","DOIUrl":"https://doi.org/10.1080/14017431.2022.2095016","url":null,"abstract":"<p><p>Current evidence base for atrial fibrillation (AF) screening is insufficient. An important finding in the STROKESTOP study was that non-participants had significantly worse outcomes. In a group of potentially non-participants feasibility of opportunistic screening in a domiciliary setting with municipality preventive home visits to citizens ≥75 years was investigated. Handheld ECG device was used by trained municipality caregivers followed by cardiologist assessment. Eighty-five percent consented to being screened, and seven of 477 screened were found with AF. Opportunistic screening in preventive home visits had a high participation rate and was feasible. Randomized trials are needed before making any firm conclusions.</p>","PeriodicalId":137876,"journal":{"name":"Scandinavian cardiovascular journal : SCJ","volume":" ","pages":"243-246"},"PeriodicalIF":2.2,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40572567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mads C T Gregers, Morten Schou, Magnus T Jensen, Jesper Jensen, Mark C Petrie, Tina Vilsbøll, Jens Peter Goetze, Peter Rossing, Peter G Jørgensen
{"title":"Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes.","authors":"Mads C T Gregers, Morten Schou, Magnus T Jensen, Jesper Jensen, Mark C Petrie, Tina Vilsbøll, Jens Peter Goetze, Peter Rossing, Peter G Jørgensen","doi":"10.1080/14017431.2022.2095435","DOIUrl":"https://doi.org/10.1080/14017431.2022.2095435","url":null,"abstract":"<p><p><b><i>Aims</i></b>. The European Society of Cardiology guidelines on diabetes and cardiovascular disease (CVD) recommend an electrocardiogram (ECG) in patients with diabetes and hypertension or with suspected CVD. We investigated whether ECG abnormalities can be used as a diagnostic and prognostic marker of heart failure (HF) in patients with type-2 diabetes (T2D) in secondary care diabetes-clinics. <b><i>Methods</i></b>. We included 722 patients with T2D in sinus rhythm. HF with preserved ejection fraction (HFpEF) was defined according to the European Society of Cardiology guidelines. Heart failure with mid-range ejection fraction (HFmrEF) was patients with dyspnoea and an LVEF 41-49%. Heart failure with reduced ejection fraction (HFrEF) or asymptomatic left ventricular systolic dysfunction (ALVSD) was defined as a LVEF ≤40%. <b><i>Results</i></b>. Overall, 24% patients had ECG abnormalities. A total of 15% had HF whereof 48% had ECG abnormalities. A normal ECG had a 99.3% negative predictive value (NPV) of ruling out HFrEF/ALVSD. In a sub-group with 0-1 simple clinical risk markers, the ECG ruled out both HFrEF/ALVSD, HFmrEF, and HFpEF with an NPV of 96.6%. The hazard-ratio (HR) of incident CVD or death in patients with HF and a normal ECG compared with patients without HF was 1.85 [95%CI 1.01-3.39], <i>p</i> = .05, while an abnormal ECG increased the HR to 3.84 [2.33-6.33], <i>p</i> < .001. <b><i>Conclusion</i></b>. HFrEF/ALVSD and HFmrEF were rare and HFpEF was frequent in this T2D population. A normal ECG ruled out HFrEF/ALVSD and in a sub-population with 0-1 simple clinical risk markers also both HFrEF/ALVSD, HFmrEF, and HFpEF.Key messages<b>What is already known about this subject?</b>In early studies of unselected patients from primary care with suspected chronic heart failure, the presence of a normal ECG was found be useful to rule out heart failure with reduced ejection fraction.<b>What does this study add?</b>This study confirms that a standard electrocardiogram when normal in 722 stable outpatients with type 2 diabetes can be used to rule out HFrEF/ALVSD. Further, it adds knowledge about the risk of incident cardiovascular disease or death as a pathologic electrocardiogram increases the hazard ratio.<b>How might this implicate clinical practice?</b>With this study clinicians in secondary diabetes care clinics can use an electrocardiogram to select patients to undergo echocardiography when suspecting heart failure with reduced ejection fraction, as a normal electrocardiogram will rule out this diagnosis with a negative predictive value of >99%.</p>","PeriodicalId":137876,"journal":{"name":"Scandinavian cardiovascular journal : SCJ","volume":" ","pages":"256-263"},"PeriodicalIF":2.2,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40603214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Filip Lyng Lindgren, Sofie Brix Christensen, Søren Lundbye-Christensen, Kristian Kragholm, Arne Johannessen, Peter Karl Jacobsen, Steen Buus Kristiansen, Peter Steen Hansen, Mogens Stig Djurhuus, Uffe Jakob Ortved Gang, Ole Dan Jørgensen, Sam Riahi
{"title":"Validation of the national Danish ablation database: a retrospective, registry-based validation study.","authors":"Filip Lyng Lindgren, Sofie Brix Christensen, Søren Lundbye-Christensen, Kristian Kragholm, Arne Johannessen, Peter Karl Jacobsen, Steen Buus Kristiansen, Peter Steen Hansen, Mogens Stig Djurhuus, Uffe Jakob Ortved Gang, Ole Dan Jørgensen, Sam Riahi","doi":"10.1080/14017431.2022.2099009","DOIUrl":"https://doi.org/10.1080/14017431.2022.2099009","url":null,"abstract":"<p><p><i>Aim</i>.To validate the National Danish Ablation Database (NDAD) by investigating to what extent data in NDAD correspond to medical records.<i>Type of study</i>. Non-blinded, registry-based, retrospective, validation study. <i>Material and methods</i>. A sample of patients who underwent ablation for atrial fibrillation in Denmark between 1 January 2016 and 31 December 2016 were included. By utilizing medical records as gold standard, positive predictive (PPV) and negative predictive values (NPV) for NDAD were assessed and presented as five main categories: arrhythmia characteristics, demographics, cardiac history, complications, and medication. PPV's and NPV's exceeding 90% were considered as high agreement. <i>Results</i>. 597 patients (71.0% males) were included in the study. Median age was 63.1 (IQR: 54.9-68.4) years. The median PPV and NPV estimates across all variables were respectively 90.4% (95% CI: 68%-95.2%) (PPV) and 99.4% (95% CI: 98.4%-99.8%) (NPV) at baseline, and 91.7% (95% CI: 67.4%-95.4%) (PPV) and 99.3% (98.2%-99.3%) (NPV) at follow-up. <i>Conclusion</i>. The data registered in NDAD agrees to a great extent with the patients' medical records, suggesting NDAD is a database with high validity. As a result of low complication rate, the PPV- and NPV-estimates among complication variables were prone to somewhat greater uncertainty compared to the rest.</p>","PeriodicalId":137876,"journal":{"name":"Scandinavian cardiovascular journal : SCJ","volume":" ","pages":"285-291"},"PeriodicalIF":2.2,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40637930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}